Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 17, 2023 - Issue
Submit an article Journal homepage
334
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants

Tommy Tsang Cheung1 Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, People’s Republic of ChinaView further author information
,
Tu H Mai2 Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA, USAView further author information
,
Yen Lin Chia2 Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA, USACorrespondence[email protected]
View further author information
,
Desmond YH Yap1 Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, People’s Republic of ChinaView further author information
,
Chi-Ho Lee1 Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, People’s Republic of ChinaView further author information
,
Cecil Chi-Keung Chen2 Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, CA, USAView further author information
,
Ying Huang3 Clinical Pharmacology, R&D China, AstraZeneca, Shanghai, People’s Republic of ChinaView further author information
,
Yuwen Jin3 Clinical Pharmacology, R&D China, AstraZeneca, Shanghai, People’s Republic of ChinaView further author information
,
James Johnston4 Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UKView further author information
,
Viktoria Werkström5 Late-Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, SwedenView further author information
,
Yuhui Yao6 Respiratory & Immunology, R&D China, AstraZeneca, Shanghai, People’s Republic of ChinaView further author information
,
Xiaoyun Ge7 Clinical Safety, R&D China, AstraZeneca, Shanghai, People’s Republic of ChinaView further author information
&
Wenying Zheng8 Biometrics, R&D China, AstraZeneca, Shanghai, People’s Republic of ChinaView further author information
 show all
Pages 209-218 | Received 04 Oct 2022, Accepted 27 Dec 2022, Published online: 26 Jan 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.